 |
|
Two-drug treatment may block source of asthma and chronic bronchitis
February 02, 2006Current treatments for asthma and chronic bronchitis aren't able to address the ultimate source of the problem-they can only alleviate symptoms. But researchers at Washington University School of Medicine in St. Louis have gone to the root of these disorders and found a two-drug treatment that could potentially restore patients' troubled airways to healthy function.
Their study appears in the February 1 issue of the Journal of Clinical Investigation.
Michael J. Holtzman, M.D., and colleagues discovered that some cells that line the air passages of the lung transform into another cell type in mice and humans with these disorders. This cellular transformation had never before been recognized and is responsible for overproduction of mucus in the airways.
The researchers found that preventing the harmful transformation of lining cells could be accomplished with two drugs, and they assert that these drugs may possibly be used in combination to normalize the airway lining in asthma and chronic bronchitis sufferers.
"In these disorders, shortness of breath and cough are related to hypersecretion of mucus in the airway," says Holtzman, the Selma and Herman Seldin Professor of Medicine and director of pulmonary and critical care medicine. "Physicians prescribe anti-inflammatory steroids and bronchodilators to ease breathing difficulties, but these medications don't specifically reduce mucus production or secretion. Our research addresses this aspect of the problem."
In mice with a chronic lung condition resembling asthma and chronic obstructive pulmonary disease (COPD), the researchers saw that the airway lining maintained an overabundance of mucus-producing cells (called goblet cells for their cup-like shape). Further investigation showed that goblet-cell buildup resulted from two cellular mechanisms. One mechanism allows for the prolonged survival of cells with cilia, tiny hairs that help sweep debris out of the lungs. The other mechanism encourages the ciliated cells to transform into goblet cells.
The researchers were the first to demonstrate this transformation from ciliated to goblet cells in a model of chronic lung disease. They also demonstrated that a similar process may occur in humans with asthma and COPD, a disease classification that includes chronic bronchitis.
"In some people, stimuli such as viral infections seem to cause a chronic excess of goblet cells and lead to persistent breathing disorders," Holtzman says. "We showed that you can block the excess of ciliated and goblet cells using a combination of two types of inhibitors."
The first of these inhibitors is newly developed and is able to impede the activity of epidermal growth factor receptor (EGFR). EGFR was persistently overactive in the ciliated airway cells in mice with the asthma-like condition. This chronic activity protected the ciliated cells from normally programmed cell death and allowed the cells to accumulate to higher than normal levels. By blocking EGFR, the inhibitor prevented the buildup of ciliated cells.
The second inhibitor the researchers tested interferes with signaling pathways activated by an immune-system protein known as interleukin-13 (IL-13). They found that IL-13 elicited the crucial change from ciliated to goblet cells in mouse airways and human airway cells in culture. Interfering with IL-13 prevented this transformation from one cell type to the other-a process known as transdifferentiation.
"Finding this sequence of events-the increase in the level of ciliated cells and then the transdifferentiation of these cells to goblet cells-opens up new treatment options that may be more effective than those tried in the past," Holtzman says. "We've shown that if you combine the EGFR and IL-13 inhibitors in a rational way, you can restore the normal architecture of the airway lining. But you have to use the combination to fully correct the abnormalities."
Holtzman believes the study's findings could readily translate into clinical treatments for asthma, COPD and other chronic airway diseases because EGFR antagonists and IL-13 inhibitors are now undergoing separate testing in the treatment of chronic airway diseases by several drug companies. The present study results should allow for better design and assessment of these inhibitors when used either alone or in combination.
Tyner JW, Kin EY, Ide K, Pelletier MR, Roswit WT, Morton JD, Battaile JT, Patel Ac, Patterson A, Castro M, Spoor MS, You Y, Brody SL, Holtzman MJ. Blocking airway mucus cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferention signals. Journal of Clinical Investigation February 2006;116(2).
Funding from the National Institutes of Health (Heart, Lung, and Blood Institute) and the Alan A. and Edith L. Wolff Charitable Trust supported this research.
Washington University School of Medicine's full-time and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
Washington University School of Medicine
The researchers found that preventing the harmful transformation of lining cells could be accomplished with two drugs, and they assert that these drugs may possibly be used in combination to normalize the airway lining in asthma and chronic bronchitis sufferers.
"In these disorders, shortness of breath and cough are related to hypersecretion of mucus in the airway," says Holtzman, the Selma and Herman Seldin Professor of Medicine and director of pulmonary and critical care medicine. "Physicians prescribe anti-inflammatory steroids and bronchodilators to ease breathing difficulties, but these medications don't specifically reduce mucus production or secretion. Our research addresses this aspect of the problem."
In mice with a chronic lung condition resembling asthma and chronic obstructive pulmonary disease (COPD), the researchers saw that the airway lining maintained an overabundance of mucus-producing cells (called goblet cells for their cup-like shape). Further investigation showed that goblet-cell buildup resulted from two cellular mechanisms. One mechanism allows for the prolonged survival of cells with cilia, tiny hairs that help sweep debris out of the lungs. The other mechanism encourages the ciliated cells to transform into goblet cells.
The researchers were the first to demonstrate this transformation from ciliated to goblet cells in a model of chronic lung disease. They also demonstrated that a similar process may occur in humans with asthma and COPD, a disease classification that includes chronic bronchitis.
"In some people, stimuli such as viral infections seem to cause a chronic excess of goblet cells and lead to persistent breathing disorders," Holtzman says. "We showed that you can block the excess of ciliated and goblet cells using a combination of two types of inhibitors."
The first of these inhibitors is newly developed and is able to impede the activity of epidermal growth factor receptor (EGFR). EGFR was persistently overactive in the ciliated airway cells in mice with the asthma-like condition. This chronic activity protected the ciliated cells from normally programmed cell death and allowed the cells to accumulate to higher than normal levels. By blocking EGFR, the inhibitor prevented the buildup of ciliated cells.
The second inhibitor the researchers tested interferes with signaling pathways activated by an immune-system protein known as interleukin-13 (IL-13). They found that IL-13 elicited the crucial change from ciliated to goblet cells in mouse airways and human airway cells in culture. Interfering with IL-13 prevented this transformation from one cell type to the other-a process known as transdifferentiation.
"Finding this sequence of events-the increase in the level of ciliated cells and then the transdifferentiation of these cells to goblet cells-opens up new treatment options that may be more effective than those tried in the past," Holtzman says. "We've shown that if you combine the EGFR and IL-13 inhibitors in a rational way, you can restore the normal architecture of the airway lining. But you have to use the combination to fully correct the abnormalities."
Holtzman believes the study's findings could readily translate into clinical treatments for asthma, COPD and other chronic airway diseases because EGFR antagonists and IL-13 inhibitors are now undergoing separate testing in the treatment of chronic airway diseases by several drug companies. The present study results should allow for better design and assessment of these inhibitors when used either alone or in combination.
Tyner JW, Kin EY, Ide K, Pelletier MR, Roswit WT, Morton JD, Battaile JT, Patel Ac, Patterson A, Castro M, Spoor MS, You Y, Brody SL, Holtzman MJ. Blocking airway mucus cell metaplasia by inhibiting EGFR antiapoptosis and IL-13 transdifferention signals. Journal of Clinical Investigation February 2006;116(2).
Funding from the National Institutes of Health (Heart, Lung, and Blood Institute) and the Alan A. and Edith L. Wolff Charitable Trust supported this research.
Washington University School of Medicine's full-time and volunteer faculty physicians also are the medical staff of Barnes-Jewish and St. Louis Children's hospitals. The School of Medicine is one of the leading medical research, teaching and patient care institutions in the nation, currently ranked third in the nation by U.S. News & World Report. Through its affiliations with Barnes-Jewish and St. Louis Children's hospitals, the School of Medicine is linked to BJC HealthCare.
Washington University School of Medicine
Chronic Bronchitis Current Events and Chronic Bronchitis News RSSWheezing and asthma in young children
The diagnosis of asthma in a young child may well be more challenging to pediatricians than previously appreciated, according to a review of research and clinical experience literature by Howard Eigen, M.D., of the Indiana University School of Medicine and Riley Hospital for Children appearing in the October 2008 issue of Clinical Pediatrics.
Common bronchodilator linked to increased deaths
A common bronchodilator drug which has been used for more than a decade by patients with chronic obstructive pulmonary disease (COPD) has been linked to a one-third higher risk of cardiovascular-related deaths.
Low level cadmium exposure linked to lung disease
New research suggests that cadmium is one of the critical ingredients causing emphysema, and even low-level exposure attained through second-hand smoke and other means may also increase the chance of developing lung disease.
Personalized therapy for asthma and COPD could soon be here
Researchers at Washington University School of Medicine in St. Louis have defined a new type of immune response that is activated in patients with severe asthma and COPD (chronic obstructive pulmonary disease). Their discovery could dramatically improve diagnosis and treatment of patients with chronic inflammatory lung disease.
Henry Ford Hospital to study effectiveness of a new procedure that may help emphysema suffers
Researchers at Henry Ford Hospital today announced the start of the EASE (Exhale Airway Stents for Emphysema) Trial, an international, multi-center clinical trial to explore an investigational treatment that may offer a significant new option for those suffering with advanced emphysema.
Life expectancy rises for the educated; the less-educated reap no benefit
It's no secret that over the last few decades, life expectancy in the United States has been rising. However, recent data shows that not everyone has benefited from this encouraging trend.
Genetic factors in smoking also increase risk of chronic bronchitis
Smoking is a known risk factor for respiratory diseases like chronic bronchitis, but genes also play a significant role in its development, according to researchers in Sweden, who studied more than 40,000 Swedish twins to determine the extent to which behavior, environment and genes each play a role ion the development of chronic bronchitis.
Clinical trials nebulized formoterol fumarate: Long-term and cardiovascular safety COPD
Data from two Phase III clinical trials were presented today in Chicago at CHEST 2007, the annual scientific assembly of the American College of Chest Physicians (ACCP), supporting the use of Perforomist (formoterol fumarate) Inhalation Solution as a safe and effective maintenance treatment for COPD patients.
Gene-chip studies provide new leads in treating lung disease of premature newborns
Some 20 to 40 percent of extremely premature infants suffer abnormal lung development leading to bronchopulmonary dysplasia, a chronic lung disease that can cause long-term breathing problems.
Some smokers have genetic predisposition to develop COPD, research shows
Some people have a genetic variation that makes them more susceptible to chronic obstructive pulmonary disease (COPD) if they smoke tobacco, according to new research from Wake Forest University School of Medicine and colleagues.
More Chronic Bronchitis Current Events and Chronic Bronchitis News Articles
 | The Chronic Bronchitis and Emphysema Handbook by François Haas, Sheila Sperber Haas "Dr. Francois Haas is an unusually gifted scientist and a compassionate human being."-HOWARD A. RUSK, M.D. Founder and Chairman, Rusk Institute The bestselling guide for chronic bronchitis and emphysema sufferers-newly revised and expanded. For the millions of people diagnosed with chronic bronchitis and/or emphysema, this bestselling guide is now revised and expanded to offer the most... |
 | Courage and Information for Life with Chronic Obstructive Pulmonary Disease: The Handbook for Patients, Families and Care Givers Managing COPD, Emphysema, Bronchitis by Rick Carter, Jo-Von Tucker, Thomas Petty, Brian Tiep, Richard Knowles Text, for consumers, covering tips, information, and details of daily living with COPD. Chapters include a dialogue between physician and patient, frequently asked questions, you and your doctors, breathing and COPD, treatment, supplemental oxygen, smoking, sleep and sex, exercise and nutrition, severe disease and treatment, surgery, and more.... |
 | Chronic Obstructive Pulmonary Disease: Practical, Medical, and Spiritual Guidelines for Daily Living With Emphysema, Chronic Bronchitis, and Combination Diagnosis (Hazelden Pocket Health Guide) by Mark Jenkins This pocket guide provides day-to-day support for living with COPD by offering immediate reference to medical information and practical approaches for dealing with the physical, emotional, disease. Mark Jenkins focuses on ways to maintain optimal physical and mental health and lays out practical management strategies for living with... |
| For Those Who Live and Breathe: A Manual for Patients With Emphysema and Chronic Bronchitis by Thomas L. Petty | |
| For Those Who Live and Breathe With Emphysema and Chronic Bronchitis | |
| Living with asthma, chronic bronchitis and emphysema, A Guide to Self-Care by n/a | |
| CHRONIC BRONCHITIS by TREVOR HENRY HOWELL | |
| Clinician's Manual on Acute Exacerbations of Chronic Bronchitis by Antonio Anzueto, Tom Schaberg Contents Introduction Pathophysiology of Chronic Bronchitis Clinical Presentation and Diagnosis of Chronic Bronchitis and AECB Management of AECB Clinical trials for AECB Nonclinical End Points: Quality of Life and Pharmacoeconomic Analysis Conclusions Suggested Reading & Appendix ... | |
 | All You Wanted to Know About Chronic Bronchitis by Savitri Ramaiah A very informative and therapeutic... |
 | Chronic exposure to volcanic environments and chronic bronchitis incidence in the Azores, Portugal [An article from: Environmental Research] by A.F.S. Amaral, A.S. Rodrigues This digital document is a journal article from Environmental Research, published by Elsevier in 2007. The article is delivered in HTML format and is available in your Amazon.com Media Library immediately after purchase. You can view it with any web browser.Description: The village of Furnas, like other active volcanic areas in the world, exhibits high levels of hazardous gases. We aimed to... |
| © 2008 BrightSurf.com |